Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 13   

Articles published

VRUS 0.0000
price chart
Sovaldi patent case hits the UK courts � decision expected Q4 2014
Sofosbuvir was initially developed in the labs of an American company called Pharmasset. Pharmasset was bought by Gilead Sciences Inc. in 2012 for $11.1bn, despite a rather complex patent landscape and contractual claims over the rights to the ...
Is Specialty Pharma Pricing At A Tipping Point?
Pharmasset Inc., the biotech company that developed the drug and which Gilead bought in 2011 for $11.2 billion, believed it could be profitable if the drug was priced at $36,000 per course of treatment, according to financial statements filed with the ...
Should Gilead Sciences, inc. Fear Incoming Competition?
But onestood out: Pharmasset's Sovaldi. Sovaldi's midstage trial results were so impressive that Gilead acquired Pharmasset for more than $11 billion in 2012; this was a jaw-dropping price tag given that Pharmasset didn't have any commercial products ...
The Pandemic We Are Ignoring
But Gilead spends only 19 percent of its revenue on research, and in any case, sofosbuvir was developed by Pharmasset Inc. at Emory University as �the result of federally funded university-based research,� according to Science Coalition, a non-profit ...
Related articles »  
AuraSense Therapeutics Welcomes Key Personnel, Further Expanding ...
During his tenure at Roche, he participated in more than 50 transactions including licensing deals with Pharmasset, InterMune, the $125MM acquisition of Mirus Bio, and led the divestment of Roche's $700MM investment in RNA therapeutics.
Related articles »  
OnCore Biopharma Agrees to Acquire Enantigen Therapeutics
The Company was founded by former executives of Pharmasset, Inc., which was acquired by Gilead Sciences in January 2012.
Related articles »  
Villanova to Dedicate Higgins Soccer Complex Saturday
Previously, he was Executive Vice President at Pharmasset, Inc., a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections.
Related articles »  
Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?
Incivek's approval, and its rapid ascent to billion-dollar blockbuster sales status, kicked off a flurry of hepatitis C research that contributed to Gilead Sciences' (NASDAQ: GILD ) massive $11 billion acquisition of Pharmasset in 2012. That deal ...
Related articles »  
Gilead Sciences: Consolidation Before The Next Step Up (GILD)
It is remarkable that Gilead bought Pharmasset for $11 B, which will be retrieved in just one year via the net income from Sovaldi.
Related articles »  
Round 2 of Gilead Sciences, Inc.'s Offensive Begins
Gilead acquired the drug in 2011 by spending $11 billion to buy Pharmasset, the drug's developer. Thanks to its success in mid- and late-stage studies, anticipation for Sovaldi was so high that doctors began warehousing all but the sickest patients up ...
Related articles »